New treatment options for advanced pancreatic cancer.
New treatment options for advanced pancreatic cancer.
复制标题
DOI：
10.1586/17474124.2.5.673
复制
发表时间：
2008-10-01
影响因子：
3.9
通讯作者：
Neoptolemos, John P
中科院分区：
文献类型：
--
作者：
Middleton, Gary;Ghaneh, Paula;Neoptolemos, John P
胰腺癌具有非常高的死亡率，并且影响全世界大约230，000个个体。吉西他滨已被确立为晚期胰腺癌的标准治疗;然而，生存优势很小。使用5-氟尿嘧啶或吉西他滨的辅助化疗现在被确立为胰腺癌的替代疗法。吉西他滨与铂剂或卡培他滨的组合可能是有利的。抗EGFR和抗VEGF药物尚未成功，但正在研究多种酪氨酸激酶抑制剂。在越来越多的免疫制剂中，GV 1001抗端粒酶疫苗引起了一些兴趣。针对重要的促有丝分裂途径的靶向剂，包括MEK/ERK、Src、PI 3 K/Akt、mTOR、Hedgehog和NF-κ B，以及靶向组蛋白脱乙酰酶、聚（ADP-核糖）聚合酶、热休克蛋白90和其他剂如β-拉帕酮的剂，对进一步开发具有相当大的兴趣。然而，个人成功的可能性很低。
Pancreatic cancer has a very high mortality rate and affects approximately 230,000 individuals worldwide. Gemcitabine has become established as the standard therapy for advanced pancreatic cancer; however, the survival advantage is small. Adjuvant chemotherapy using either 5-fluorouracil or gemcitabine is now established in pancreatic cancer as an alternative therapy. Combinations of gemcitabine with either platin agents or capecitabine may be advantageous. Anti-EGFR and anti-VEGF agents have been unsuccessful but multiple tyrosine kinase inhibitors are under investigation. Of the increasing number of immunological agents, the GV1001 antitelomerase vaccine holds some interest. Targeted agents against important mitogenic pathways, including MEK/ERK, Src, PI3K/Akt, mTOR, Hedgehog and NF-kappaB, as well as agents targeting histone deacetylase, poly(ADP-ribose) polymerase, heat shock protein 90 and other agents such as beta-lapachone, hold considerable interest for further development. However, the probability of individual success is low.